BIO

Bio-Rad LaboratoriesD

NYSE / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-21

Current thesis

The bull case is that core operations are proving more durable than the headline GAAP loss suggests: Q1 reported sales still grew, Bio-Rad remained cash generative, repurchased shares, and activist involvement may sharpen capital-allocation discipline.

Posture

Defensive

Lead driver

Value

What changed

Value remains the lead driver in the composite, 7D delta +0.1.

What can break

Academic research demand remains soft, especially in the Americas, pressuring constant-currency Life Science growth. [#SEC-8K-2026-04-30]

Momentum

Value

Sentiment

Setup hits (3d)

0 · Net Neutral

AI TargetsBase $305.00 · Bull $340.00 · Bear $245.00

Data freshness

Prices

As of 2026-07-21

Fundamentals

As of 2026-07-20 • Vendor: Data Vendor v1

Scores

As of 2026-07-21 • Model: HYBRID_IC_RP

AI Memo

As of 2026-06-22 • Model: RankAlpha Sentiment Codex

Investment thesis

As of 2026-07-21

Supporting evidence

What

Grade D · Defensive

Confidence Medium · Net Neutral

Target $301.25

Why

Momentum29 · Δ7d +7.1

Value64 · Δ7d +0.1

Sentiment47 · Δ7d -4.5

So what

Weak posture (Net Neutral). Prioritize risk control and patience.

Lead driver: Value · See fundamentals

Momentum

26% active weight

Current posture

7d trendSoftening

Δ7d

+7.1

Δ21d

-1.4

Value

39% active weight

Current posture

7d trendFlat

Δ7d

+0.1

Δ21d

-0.3

Sentiment

34% active weight

Current posture

7d trendSoftening

Δ7d

-4.5

Δ21d

-6.1

Why this grade

Composite grade D. Momentum 29.4 / Value 64.0 / Sentiment 46.9

Fundamentals (TTM)

As of 2026-07-20

Market Cap

$8.12B

Beta

1.18

Shares Out

26.76M

P/E (TTM)

27.2

P/S (TTM)

3.38

P/FCF (TTM)

25.65

Rev YoY

+1.1%

EPS YoY

-954.0%

Gross Margin

+51.8%

Op Margin

+8.5%

Net Debt

-$157.4M

Current Ratio

3.21

As of 2026-07-21 • Updated nightlySource: Internal modelMethodology